Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
GB-4362
Generate Biomedicines
Advanced Urothelial Cancer
1 trial -
GB-5267 - IV only
Generate Biomedicines
Platinum-resistant Ovarian Cancer
1 trial -
GB-7624
Generate Biomedicines
Atopic Dermatitis (AD)
1 trial -
GEN1042
Genmab A/S
Malignant Solid Tumor
1 trial -
GPC3 and/or TGFβ targeting CAR-T cells
The First People's Hospital of Lianyungang
Hepatocellular Carcinoma
1 trial -
GRNOPC1
Lineage Cell Therapeutics
Spinal Cord Injury
1 trial -
GRoningen Early-PD Ambroxol Treatment Pharmacokinetics
Disc Medicine
Parkinson's disease
1 trial -
GTB-5550
GT Biopharma
Tri-specific Killer Engager
1 trial -
GTX-104
Grace Therapeutics
Aneurysmal Subarachnoid Hemorrhage
1 trial -
Garetosmab
Regeneron UK Limited
Obesity
1 trial -
Gemtuzumab Ozogamicin
Jazz Pharmaceuticals Ireland Limited
Acute Myelogenous Leukemia
1 trial -
Glucophage® XR 750 mg Tablets
Teva Pharma GmbH
Healthy
2 trials -
H5.001CBCFTR
Ultragenyx UK Limited
Cystic Fibrosis
1 trial -
HD204
Prestige Biopharma Belgium
Healthy Volunteers
1 trial -
HER2 Tumor Vaccine
The First People's Hospital of Lianyungang
Adenocarcinoma - GEJ
1 trial -
HSV 2 Formulation 1
Lxo Ireland Designated Activity Company
Genital Herpes
1 trial -
HTLP-onco-adult - A phase I/II Study evaluating the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after umbilical cord blood (UCB) transplantation in adult patients with hematologic malignancies
Pari Pharma GmbH
hematologic malignancies ; acute myeloid leukemias
1 trial -
HWK-016, MUCIN-16-targeted ADC
CATALYST PHARMACEUTICALS, INC.
PROC
1 trial -
Human BCMA targeted T Cells Injection
The First People's Hospital of Lianyungang
Multiple Myeloma
1 trial -
Hutrukin
XBiotech Germany GmbH
Pharmacokinetics
1 trial -
IDE034
IDEAYA Biosciences
Esophageal Squamous Cell Carcinoma
1 trial -
IFx-Hu2.0
TuHURA Biosciences, Inc./NV
Cutaneous Melanoma, Stage III
1 trial -
INC280 single agent
Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
1 trial -
INO-3106, INO-9012
INOVIO PHARMACEUTICALS, INC.
Aerodigestive Precancerous Lesions and Malignancies
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources